Annexin Pharmaceuticals AB (publ) (STO:ANNX)

Sweden flag Sweden · Delayed Price · Currency is SEK
15.90
+1.40 (9.66%)
Apr 24, 2026, 3:00 PM CET
Market Cap112.24M -45.1%
Revenue (ttm)n/a
Net Income-39.44M
EPSn/a
Shares Out7.06M
PE Ration/a
Forward PE5.73
Dividendn/a
Ex-Dividend Daten/a
Volume6,463
Average Volume9,013
Open15.00
Previous Close14.50
Day's Range14.95 - 16.30
52-Week Range11.65 - 41.20
Beta0.24
RSI60.99
Earnings DateMay 13, 2026

About STO:ANNX

Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmology, oncology, sickle cell disease, and cardiovascular disease. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 4
Stock Exchange Nasdaq Stockholm
Ticker Symbol ANNX
Full Company Profile

Financial Performance

Financial Statements